148 related articles for article (PubMed ID: 11307097)
1. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.
Zervox EE; Franz MG; Salhab KF; Shafii AE; Menendez J; Gower WR; Rosemurgy AS
J Gastrointest Surg; 2000; 4(6):614-9. PubMed ID: 11307097
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
Wang X; Fu X; Brown PD; Crimmin MJ; Hoffman RM
Cancer Res; 1994 Sep; 54(17):4726-8. PubMed ID: 8062271
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
[TBL] [Abstract][Full Text] [Related]
5. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
Haq M; Shafii A; Zervos EE; Rosemurgy AS
Cancer Res; 2000 Jun; 60(12):3207-11. PubMed ID: 10866312
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
[TBL] [Abstract][Full Text] [Related]
7. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.
Jimenez RE; Hartwig W; Antoniu BA; Compton CC; Warshaw AL; Fernández-Del Castillo C
Ann Surg; 2000 May; 231(5):644-54. PubMed ID: 10767785
[TBL] [Abstract][Full Text] [Related]
8. EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Durkin AJ; Osborne DA; Yeatman TJ; Rosemurgy AS; Armstrong C; Zervos EE
J Surg Res; 2006 Sep; 135(1):195-201. PubMed ID: 16678855
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis.
Muhs BE; Patel S; Yee H; Marcus S; Shamamian P
J Surg Res; 2003 Feb; 109(2):110-7. PubMed ID: 12643851
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
Zervos EE; Shafii AE; Haq M; Rosemurgy AS
J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
[TBL] [Abstract][Full Text] [Related]
11. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
[TBL] [Abstract][Full Text] [Related]
12. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20.
Bu W; Tang ZY; Sun FX; Ye SL; Liu KD; Xue Q; Chen J; Gao DM
Hepatogastroenterology; 1998; 45(22):1056-61. PubMed ID: 9756006
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
14. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
16. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms.
Bigatel DA; Elmore JR; Carey DJ; Cizmeci-Smith G; Franklin DP; Youkey JR
J Vasc Surg; 1999 Jan; 29(1):130-8; discussion 138-9. PubMed ID: 9882797
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Chavey C; Mari B; Monthouel MN; Bonnafous S; Anglard P; Van Obberghen E; Tartare-Deckert S
J Biol Chem; 2003 Apr; 278(14):11888-96. PubMed ID: 12529376
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.
Watson SA; Morris TM; Robinson G; Crimmin MJ; Brown PD; Hardcastle JD
Cancer Res; 1995 Aug; 55(16):3629-33. PubMed ID: 7627972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
